Evidence map›Paper›PMID 41479572›Full record

ArticleActa naturae

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

A I Radchenko, E V Kuzubova, A A Apostol, V A Mitkevich, L A Andreeva, S A Limborska, Yu V Stepenko, V S Shmigerova, A V Solin, M V Korokin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A I RadchenkoBelgorod State National Research University, Belgorod, 308015 Russia.
E V KuzubovaBelgorod State National Research University, Belgorod, 308015 Russia.
A A ApostolBelgorod State National Research University, Belgorod, 308015 Russia.
V A MitkevichEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
L A AndreevaNational Research Center "Kurchatov Institute", Moscow, 123182 Russia.
S A LimborskaNational Research Center "Kurchatov Institute", Moscow, 123182 Russia.
Yu V StepenkoBelgorod State National Research University, Belgorod, 308015 Russia.
V S ShmigerovaBelgorod State National Research University, Belgorod, 308015 Russia.
A V SolinBelgorod State National Research University, Belgorod, 308015 Russia.
M V KorokinBelgorod State National Research University, Belgorod, 308015 Russia.
M V PokrovskiiBelgorod State National Research University, Belgorod, 308015 Russia.
N F MyasoedovNational Research Center "Kurchatov Institute", Moscow, 123182 Russia.
A A MakarovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease, first described over a century ago, is currently among the most common neurodegenerative diseases whose significance is increasingly growing with the aging of populations. Throughout the entire period of its study, no remedies have been found that would be effective in treating - or at least significantly slowing - the pathological process, while being sufficiently safe. In this regard, significant attention is paid to the development and application of natural peptide drugs lacking side effects. The present study assessed the effect of the known neuroprotective peptide Semax and its derivative on the behavioral characteristics and development of amyloidosis in transgenic APPswe/PS1dE9/Blg mice acting as a model of Alzheimer's disease. The open field, novel object recognition, and Barnes maze tests demonstrated that both Semax and its derivative improved cognitive functions in mice. Histological examination showed that these peptides reduced the number of amyloid inclusions in the cortex and hippocampus of the animals' brains. These findings demonstrate the high potential of Semax and its derivatives when used to develop therapeutic and corrective strategies for Alzheimer's disease.

Indexed as

Alzheimer’s diseaseamyloidosisbehavioral testinghistological analysispeptide drug

Identifiers

PMID41479572
PMCPMC12755871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.